Table 1.
Clinicopathological characteristics of patients and cancers included in study
| All patients | Patients assessable for RAD51 |
|
|---|---|---|
|
| ||
| n | 68 | 57 |
| Median Age | 47 (29-67) | 48 (29-67) |
| Pathology | ||
| IDC | 53 | 45 |
| ILC | 11 | 9 |
| Other | 2 | 1 |
| Median tumour size (range mm) | 51 (20-110) | 53 (21-110) |
| Grade | ||
| 1 | 1 | 0 |
| 2 | 29 | 25 |
| 3 | 32 | 29 |
| Axillary node positive | 54% (30/52) | 55% (25/45) |
| ER positive | 64% (41/64) | 63% (35/55) |
| HER2 positive | 19% (10/52) | 18% (9/49) |
| Menopausal status | ||
| Pre | 38 | 36 |
| Peri | 2 | 2 |
| Post | 16 | 14 |
| Chemotherapy | ||
| AC | 36 | 28 |
| FEC | 5 | 4 |
| ECisF | 14 | 14 |
| ECycloF | 5 | 4 |
| NE | 8 | 7 |
| Tamoxifen | 82% (48/58) | 79% (43/54) |
| Clinical response | ||
| CR | 12 | 10 |
| PR | 38 | 35 |
| SD | 12 | 7 |
| PD | 3 | 3 |
| path CR | 10% (6/60) | 10% (5/49) |
Eleven tumours had no proliferation in the post chemotherapy biopsy and were not assessable for RAD51. IDC – Invasive ductal carcinoma; ILC – Invasive lobular carcinoma. Chemotherapy – AC (Doxorubicin, Cyclophosphamide), FEC (Fluorouracil, Epirubicin, Cyclophosphamide), ECisF (Epirubicin, Cisplatin, infusional Fluorouracil), ECycloF (Epirubicin, Cyclophosphamide, infusional Fluorouracil), NE (Navelbine, Epirubuicin) (35, 36). Clinical response; CR – complete response; PR – partial response; SD – stable disease; PD – progressive disease.